Naveglitazar (racemate) is a synthetic compound that belongs to the class of dual PPAR (peroxisome proliferator-activated receptor) agonists, specifically targeting PPARα and PPARγ. This compound is primarily investigated for its potential therapeutic applications in the management of metabolic disorders, including type 2 diabetes and dyslipidemia. As a racemic mixture, Naveglitazar consists of two enantiomers, which may exhibit different pharmacological properties and effects. The substance is characterized by its ability to modulate lipid metabolism and improve insulin sensitivity, making it a candidate for addressing conditions associated with metabolic syndrome. In terms of its chemical structure, Naveglitazar features functional groups that facilitate its interaction with PPAR receptors, leading to the activation of genes involved in fatty acid oxidation and glucose homeostasis. Safety and efficacy profiles are typically evaluated through preclinical and clinical studies, and ongoing research aims to elucidate its full therapeutic potential and any associated side effects.

Naveglitazar (racemate)

916085-47-7: Naveglitazar (racemate) is a synthetic compound that belongs to the class of dual PPAR (peroxisome proliferator-activated receptor) agonists, specifically targeting PPARα and PPARγ. This compound is primarily investigated for its potential therapeutic applications in the management of metabolic disorders, including type 2 diabetes and dyslipidemia. As a racemic mixture, Naveglitazar consists of two enantiomers, which may exhibit different pharmacological properties and effects. The substance is characterized by its ability to modulate lipid metabolism and improve insulin sensitivity, making it a candidate for addressing conditions associated with metabolic syndrome. In terms of its chemical structure, Naveglitazar features functional groups that facilitate its interaction with PPAR receptors, leading to the activation of genes involved in fatty acid oxidation and glucose homeostasis. Safety and efficacy profiles are typically evaluated through preclinical and clinical studies, and ongoing research aims to elucidate its full therapeutic potential and any associated side effects.

Naveglitazar racemate is the racemate of Naveglitazar.

CAS 916085-47-7

Naveglitazar (racemate)

Naveglitazar racemate

Ref: TM-T12185